Anti-cxcr1 compositions and methods

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 5/095 (2010.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) G01N 33/574 (2006.01)

Patent

CA 2743305

The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non- tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).

La présente invention porte sur des méthodes de traitement du cancer par l'administration d'un inhibiteur de la voie IL8-CXCR1 (par exemple, un anticorps anti-CXCR1 ou la répertaxine), seul ou en combinaison avec un agent chimiothérapeutique supplémentaire, de telle sorte que les cellules cancéreuses non-tumorigènes et tumorigènes chez un sujet sont détruites. La présente invention porte également sur des compositions et des procédés pour détecter la présence et isoler des cellules souches de tumeur solide chez un patient (par exemple, sur la base de la présence de CXCR1 ou FBXO21).

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Anti-cxcr1 compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cxcr1 compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cxcr1 compositions and methods will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1521053

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.